Tuesday, March 21, 2023
Clinical Advances in
New biologics with a novel mechanism of action offer new options for patients with inflammatory bowel disease (IBD) not optimally controlled with anti-tumor necrosis factor (TNF) agents. Integration of biologics into clinical practice together with emerging strategies for management of IBD -- including early intervention, new treatment goals, and personalized care -- will allow physicians to improve patient outcomes and potentially alter the progressive course of IBD.
Supported by an independent educational grant from
Educational slides on new biologic agents and treatment strategies in IBD
Download
Steering Committee Chair
Gastroenterologist
Guy's and St Thomas' Hospital
London, United Kingdom
Professor
Humanitas University
Rozzano, Italy
Professor of Practice
St. Mark's Hospital
Department of Surgery and Cancer
Imperial College
London, UK
Professor
Academic Medical Center
Amsterdam, The Netherlands
Professor of Medicine
Department of Gastroenterology and Hepatology
University Hospital of Zürich
University of Zürich
Zurich, Switzerland
Professor of Medicine
Department of Internal Medicine I
Kiel University
Kiel, Germany
Steering Committee Chair
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AbbVie Inc.; Eli Lilly and Company; Janssen Pharmaceuticals; Samsung Bioepis Co., Ltd.; Sandoz International GmbH; Takeda Pharmaceuticals North America, Inc.; Topivert, Ltd.; VHsquared, Ltd.
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Falk Pharma; Ferring Pharmaceuticals; Janssen Pharmaceuticals; Pfizer Inc.; Sandoz International GmbH; Shire; Takeda Pharmaceuticals North America, Inc.; Tillotts Pharma AG
Received grants for clinical research from: Janssen Pharmaceuticals; Merck Sharp & Dohme, Corp.; Takeda Pharmaceuticals North America, Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AbbVie Inc.; Actial Pharmaceuticals; Allergan, Inc.; Amgen Inc.; AstraZeneca Pharmaceuticals LP; Biogen; Boehringer Ingelheim Pharmaceuticals, Inc.; Celgene Corporation; Celltrion; Ferring Pharmaceuticals; Gilead Sciences, Inc.; Hospira; Janssen Pharmaceuticals; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Merck Sharp & Dohme Corp; Mundipharma; Pfizer Inc.; Roche Holding AG; Sandoz; Takeda Pharmaceuticals North America, Inc.; UCB Pharma, Inc.; Vifor Pharm
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AbbVie Inc.; Atlantic; Bristol-Myers Squibb Company; Celltrion; Falk Pharma; Ferring Pharmaceuticals; Gilead Sciences, Inc.; Janssen Pharmaceuticals; Merck Sharp & Dohme Corp; Napp Pharmaceuticals Limited; Pfizer Inc.; Pharmacosmos; Shire; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for:AbbVie Inc.; Atlantic; Bristol-Myers Squibb Company; Celltrion; Falk Pharma; Ferring Pharmaceuticals; Gilead Sciences, Inc.; Janssen Pharmaceuticals; Merck Sharp & Dohme Corp; Napp Pharmaceuticals Limited; Pfizer Inc.; Pharmacosmos; Shire; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: AbbVie Inc.; Takeda Pharmaceuticals North America, Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AbbVie Inc.; Celgene Corporation; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Pfizer Inc.; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: AbbVie Inc.; Pfizer Inc.; Takeda Pharmaceuticals North America, Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for:AbbVie Inc.; Augurix; Bristol-Myers Squibb Company; Boehringer Ingelheim Pharmaceuticals, Inc.; Calypso; Celgene Corporation; FALK; Ferring Pharmaceuticals; Fisher; Genentech, Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals; MerckSharp & Dohme; Novartis Pharmaceuticals Corporation; Pfizer Inc.;Phadia; Roche Holdings AG; UCB Pharma, Inc.; Takeda Pharmaceuticals North America, Inc.; Tillots; Vifor Pharma; Vital Solutions; Zeller
Served as a speaker or a member of a speakers bureau for:AstraZeneca Pharmaceuticals LP; AbbVie Inc.; FALK; Janssen Pharmaceuticals; Merck Sharp & Dohme; Pfizer Inc.; Phadia; Takeda Pharmaceuticals North America, Inc.; Tillots; UCB Pharma, Inc.; Vifor Pharma; Zeller
Received grants for clinical research from:AbbVie Inc.; Ardeypharm; Augurix; Calypso; FALK; Flamentera; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche; Takeda Pharmaceuticals North America, Inc.; Tillots; UCB Pharma, Inc.; Zeller
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Celltrion; Ferring Pharmaceuticals; IMAD; Janssen Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche Holding AG; Takeda Pharmaceuticals North America, Inc.
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Amgen Inc.; Celltrion; Falk; Janssen Pharmaceuticals; Merck & Co., Inc.; Takeda Pharmaceuticals North America, Inc.